A Cochrane review included 6 studies with a total of 159 subjects. No data were pooled for analysis due to differences in outcomes and methodology among the included studies. One small study shows a positive benefit for induction of remission (RR 19.00, 95% CI 1.27 to 284.24, n=18). Patients were maintained on their existing long-term medication with sulphasalazine or mesalazine. Some of the other included studies show some positive benefits for secondary outcomes.
Comment: The quality of evidence is downgraded by imprecise results (limited study size for each comparison) and by inconsistency (heterogeneity in interventions and outcomes).